Neurological effects of COVID-19 in pediatric patients with the multisystem inflammatory syndrome in children (MIS-C). | ||||
Minia Journal of Medical Research | ||||
Articles in Press, Accepted Manuscript, Available Online from 04 May 2023 | ||||
Document Type: Original Article | ||||
DOI: 10.21608/mjmr.2023.187892.1308 | ||||
View on SCiNiTO | ||||
Authors | ||||
Nagwa M. Sabry Mahmoud1; Ahmed Fathy Khalil 2; Moustafa Abd ElRheem1 | ||||
1Pediatric Department, Faculty of Medicine, Minia University, Egypt | ||||
2Assiut General Hospital, Assiut, Egypt | ||||
Abstract | ||||
Background: In December 2019, people residing in the Chinese region of Wuhan were reported to have developed a severe form of pneumonia brought on by a novel coronavirus that is now known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Since then, cases of COVID-19, have been documented from every nation in the world. Objective: To assess the neurological impact in paediatric patients with COVID-19-associated Multisystem Inflammatory Syndrome in Children (MIS-C). Methods: Patients who were admitted to Minia University Hospital's Pediatric Intensive Care Unit (PICU) isolation unit between December 2020 and July 2022 were included in this cross-sectional study. We investigated at a total of 368 patients, of which 62 had PCR results that were positive for covid. Results: Convulsions was demonstrated among the patients by 20 (31.7%), p-value<0.0001. followed by DCL was 18 (28.2%)p-value<0.0001. Headache was also demonstrated among the patients also by 18 (28.2%)p-value<0.0001. Weakness was also demonstrated among the patients 18 (28.3%)p-value<0.0001. While, drowsiness among patients was (9 (14.52%), p-value<0.0001. Hypertonia, hyperreflexia, hypotonia, hyporeflexia, 4 (3.5%) and2 (1.7%) respectively. The majority of the patients had abnormal ground glass opacities on their chest scans (CO-RADS III). The number of patients who had neurological manifestations show significantly increased mortality. Conclusion: paediatric patients with SARS-CoV-2 infection may have life-threatening neurological disorders, even if only neurologic symptoms are present, patients should be tested for SARS-CoV-2 due to its prevalence in children. In addition, many of these patients arrived at the hospital unaware of COVID-19 exposure and positivity, so testing is necessary. | ||||
Keywords | ||||
COVID-19; multisystem inflammatory syndrome in children (MIS-C); pediatrics; neurological symptoms; SARS-CoV-2 | ||||
Statistics Article View: 137 |
||||